UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-36309 INOGEN, INC. (Exact name of registrant as specified in its charter) Delaware 33-0989359 (State or other jurisdiction of i ...

Inogen, Inc. (INGN) incurred an adjusted loss per share of 11 cents for first-quarter 2025, which was narrower than the adjusted loss per share of 45 cents in the year-ago period and the Zacks Consensus Estimate of a loss of 52 cents per share. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)GAAP loss per share for the quarter was 25 cents, narrower than the year-earlier loss of 62 cents.INGN’s Revenues in DetailInogen registered revenues of $82.3 million for the first quarter, up 5 ...

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Inogen shares have lost about 22.9% since the beginning of the year versus the S&P 500's decline of -4.7%. What's Next for Inogen? Inogen (INGN) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.62 per share a year ago. These fig ...

Inogen (INGN) Q1 2025 Earnings Call May 07, 2025 05:00 PM ET Speaker0 Welcome to Inogen's First Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. Following management's prepared remarks, we will hold a Q and A session. As a reminder, this conference is being recorded today, 05/07/2025. I would now like to turn the call over to Ryan Peterson, Investor Relations. Speaker1 Thank you all for participating in today's call. Joining me are President and ...

May 7, 2025 Q1 2025 Supplemental Financial Information Use of Non-GAAP Financial Measures Inogen has presented certain financial information in accordance with U.S. GAAP and also on a non-GAAP basis for the three months ended March 31, 2025, and March 31, 2024. Management believes that non-GAAP financial measures, taken in conjunction with U.S. GAAP financial measures, provide useful information for both management and investors by excluding certain non-cash and other expenses that are not indicative of Ino ...

Exhibit 99.1 Inogen Announces First Quarter 2025 Financial Results GOLETA, Calif., May 7, 2025 -- Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended March 31, 2025. "Inogen's strong first quarter financial results underscore our success in driving improved commercial and operational execution," said Kevin Smith, President and Chief Executive Officer. "We are making great p ...

For the quarter ended December 2024, Inogen (INGN) reported revenue of $80.08 million, up 5.5% over the same period last year. EPS came in at -$0.41, compared to -$1.14 in the year-ago quarter.The reported revenue represents a surprise of +0.73% over the Zacks Consensus Estimate of $79.5 million. With the consensus EPS estimate being -$0.57, the EPS surprise was +28.07%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street exp ...

Core Insights - A new management team and business strategy at Inogen are yielding positive results, focusing on creating a more stable business model by prioritizing sales to durable/home markets [1] Group 1 - The company is a small-cap manufacturer of portable oxygen concentrators [1] - The shift in strategy aims to enhance stability in the business model [1] - The emphasis on durable/home sales indicates a strategic pivot to cater to a specific market segment [1]

Financial Performance and Risks - The company experienced a net foreign currency loss of $0.2 million for the year ended December 31, 2024, compared to a gain of $0.2 million in 2023 and a loss of $0.8 million in 2022[192]. - The majority of the company's revenue is derived from rentals or sales generated from its direct sales force, and failure to maintain or expand this force could adversely affect financial results[198]. - The company expects that existing capital resources and cash generated from expected product sales will be sufficient to meet projected operating and investing requirements for at least the next twelve months[15]. - The company's quarterly revenue and results of operations have shown significant variability, which may lead to stock price volatility[214]. - Projections regarding the size of the oxygen therapy market may be overly optimistic, potentially adversely affecting revenues[216]. - Changes in tax legislation, such as the Tax Cuts & Jobs Act and the Inflation Reduction Act, could materially impact the company's financial condition and effective tax rate[218]. - The company operates in multiple taxing jurisdictions, and changes in tax interpretations could materially impact sales and use tax liabilities[219]. - The ability to recognize deferred tax assets depends on future cash flows and taxable income, with significant estimates required for recoverability[220]. - The company incurred an impairment charge of $32.9 million in the quarter ended September 30, 2023, due to a decline in stock price affecting market capitalization[282]. - The stock price has fluctuated significantly, trading as high as $13.33 and as low as $5.08 per share in the last twelve months[280]. Regulatory Compliance and Legal Risks - The company faces significant risks and liabilities if it fails to comply with anti-bribery and anti-corruption laws, which could result in severe penalties and impact its reputation and business[194]. - The company is subject to extensive federal and state regulations, and non-compliance could result in severe sanctions and operational changes[225]. - As a healthcare provider, the company is under strict scrutiny to prevent fraud and abuse, which could lead to audits and investigations[226]. - Regulatory changes in healthcare laws may affect permissible activities and reimbursement amounts, potentially impacting business operations[227]. - The company must obtain and maintain necessary regulatory clearances for its medical devices, with the FDA having the authority to revoke approvals[228]. - Delays in obtaining FDA clearances could adversely affect the introduction of new products, impacting sales[231]. - Non-compliance with FDA's Quality System Regulation could interrupt manufacturing operations and negatively affect sales and financial results[240]. - The company must comply with various international standards, including ISO, to avoid adverse actions from foreign regulatory bodies, which could negatively impact its reputation and financial condition[242]. - In the European Union, medical devices are regulated under the MDR, which requires compliance before commercial distribution, affecting market opportunities[243]. - Failure to obtain and maintain regulatory approvals in foreign jurisdictions could limit market opportunities and negatively affect revenues and overall market penetration[244]. - The company may face significant penalties if it is determined to be promoting products for unapproved or off-label uses, which could damage its reputation[249]. - Compliance with HIPAA and HITECH Act is crucial, as violations could result in significant civil and criminal penalties, adversely affecting financial condition[250]. - The company is subject to the Federal Anti-Kickback Statute and the Physician Self-Referral Law, which could lead to substantial penalties if not adhered to[254][255]. - The Federal False Claims Act allows for civil monetary penalties and exclusion from federal healthcare programs for presenting false claims, which could materially affect operations[256]. - The company must report payments to physicians under the Physician Payments Sunshine Act, with penalties for non-compliance potentially reaching $150,000 annually[257]. - Increased regulation of payments to physicians may lead to compliance challenges, increasing the risk of violations[258]. - Non-compliance with healthcare laws could result in penalties, fines, and operational restrictions, harming the company's ability to operate effectively[260]. - The implementation of prior authorization rules for DMEPOS under Medicare could negatively affect the company's business and financial condition, particularly for items with an average purchase fee of $1,000 or greater[264]. - The company is exposed to risks related to fraud, misconduct, or illegal activities by employees and third parties, which could lead to significant fines or sanctions[261]. Operational and Strategic Risks - The company relies on shipping providers for global product delivery, and disruptions could adversely affect financial condition and results of operations[193]. - The company may be subject to substantial warranty or product liability claims, which could require significant expenditures to defend and adversely affect financial condition[199]. - The company experienced significant turnover in its senior executive team in 2024, which could impact its strategic priorities and business continuity[203]. - The company relies heavily on information technology networks and systems, and any disruptions could lead to material losses and legal liabilities[204]. - A recent cyberattack on a third-party service provider caused delays in rental revenue collections, highlighting vulnerabilities in the company's operations[206]. - The company anticipates future supply chain constraints and is assessing the impact of expense inflation on its products[15]. - The company is focused on developing new products and improving existing ones to increase their value[15]. - Foreign governments impose strict price controls on medical devices, which may adversely affect the company's future profitability and long-term growth[262]. Intellectual Property and Competitive Risks - The company relies on patents and other intellectual property to protect its products, and failure to secure or maintain these protections could harm its competitive advantage and profitability[265]. - The company faces risks of patent infringement claims from competitors, which could result in substantial damages or the need to cease selling certain products[269]. - The company must monitor unauthorized use of its intellectual property, which is costly and may lead to litigation that diverts resources and attention[268]. - The company’s ability to compete may be harmed if it cannot prevent unauthorized use or disclosure of its trade secrets and proprietary information[274]. - The company may be subject to damages from claims related to the wrongful use or disclosure of trade secrets from former employers of its employees[275]. Corporate Governance and Shareholder Matters - As of December 31, 2024, executive officers, directors, and stockholders owning more than 5% of outstanding common stock controlled approximately 33.1% of shares, providing them substantial influence over corporate actions[290]. - The company has never paid dividends on its capital stock and does not anticipate paying any cash dividends in the foreseeable future, focusing instead on retaining earnings for business growth[294]. - Compliance with the Sarbanes-Oxley Act requires annual assessment of internal control over financial reporting, leading to substantial accounting expenses and management time[278]. - The company may face increased legal, accounting, and compliance costs due to public company regulations, impacting operational efficiency[279]. - The exclusive forum provisions in the company's bylaws may limit stockholders' ability to bring claims in their preferred judicial forum, potentially increasing litigation costs[287]. - Future sales of shares could lead to a decline in stock price and make it more challenging to sell equity securities at favorable terms[288]. - The company may issue additional shares or securities in the future, which could result in substantial dilution for existing stockholders[289].

Medical Technology company Inogen Inc INGN reported a fourth-quarter adjusted EPS loss of 24 cents, compared to a loss of 83 cents a year ago, beating the consensus loss of 61 cents.The company reported sales of $80.1 million, beating the consensus of $73.9 million.Total revenue in the fourth quarter of 2024 increased 5.5% year over year, primarily driven by higher demand and new customers in international and domestic business-to-business sales, partially offset by lower direct-to-consumer sales and lower ...